SCHEDULE: BVF Discloses 9.99% Stake in TScan Therapeutics

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in TScan Therapeutics, Inc. following recent warrant exercises.

Summary

• The reporting group, led by Mark N. Lampert and BVF Partners L.P., holds a combined 5,578,288 shares of TScan Therapeutics common stock.
• This ownership represents 9.99% of the company's outstanding shares as of March 31, 2026.
• The stake includes shares acquired through the exercise of Pre-Funded Warrants on March 27, 2026.
• The reporting persons hold additional Pre-Funded Warrants, but their exercise is currently limited by a 9.99% ownership blocker provision.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure reflecting standard institutional portfolio management rather than a strategic shift in company operations.

Positives

• Significant institutional backing from a specialized biotechnology investment firm.
• Demonstrated long-term commitment through the exercise of warrants and continued holding of equity.

Negatives

• The 9.99% ownership blocker prevents the immediate conversion of remaining warrants, capping the current voting and economic influence of the reporting group.

Risks

• The 9.99% ownership blocker limits the ability of the reporting group to increase their stake without triggering regulatory or contractual constraints.
• Market volatility in the biotechnology sector could impact the value of the underlying equity.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional accumulation of shares in clinical-stage biotech companies like TScan Therapeutics often signals confidence in the underlying pipeline, though it remains a passive investment in this instance.

Comparison to Industry Standards

• The 9.99% ownership cap is a standard 'blocker' provision in biotech financing to avoid triggering change-of-control clauses or complex regulatory filings.
• The use of Pre-Funded Warrants is a common mechanism in biotech capital raises to provide immediate capital while deferring full equity dilution.

Stakeholder Impact

• Shareholders may view the continued investment by a specialized biotech fund as a vote of confidence in the company's long-term prospects.

Next Steps

• Continued monitoring of the reporting group's holdings for further changes in ownership percentage.

Key Dates

Keywords

TScan Therapeutics, BVF Partners, Biotechnology, Schedule 13G, Institutional Ownership, Pre-Funded Warrants